Biotech · Private company

Kite, A Gilead Company

Track this companyFree. Adds Kite, A Gilead Company to your Dealase workspace and tells you when its record changes.

Clinical trials2524 recruiting or active

Pipeline programs50From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline50

Anitocabtagene AutoleucelPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Axicabtagene CiloleucelPhase 3 · High-risk Large B-cell Lymphoma (LBCL)ClinicalTrials.gov · fetched Nov 12, 2026
Axicabtagene CiloleucelPhase 3 · Relapsed or Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Axicabtagene CiloleucelPhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
BortezomibPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · High-risk Large B-cell Lymphoma (LBCL)ClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Relapsed or Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
DexamethasonePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
DoxorubicinPhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
DoxorubicinPhase 3 · High-risk Large B-cell Lymphoma (LBCL)ClinicalTrials.gov · fetched Nov 12, 2026
EtoposidePhase 3 · High-risk Large B-cell Lymphoma (LBCL)ClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · High-risk Large B-cell Lymphoma (LBCL)ClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Relapsed or Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
KITE-753Phase 3 · Relapsed or Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
LenalidomidePhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
PomalidomidePhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 3 · High-risk Large B-cell Lymphoma (LBCL)ClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Relapsed and/or Refractory B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Relapsed and/or Refractory B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
KITE-363Phase 2 · Relapsed and/or Refractory B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
KITE-753Phase 2 · Relapsed and/or Refractory B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
anito-celPhase 1 · Muscular DiseasesClinicalTrials.gov · fetched Nov 12, 2026
anitocabtagene-autoleucelPhase 1 · Relapsed and Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
ARC-T CellsPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Relapsed/Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Muscular DiseasesClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Relapsed/Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Muscular DiseasesClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
KITE-197Phase 1 · Relapsed/Refractory Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
KITE-363Phase 1 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
KITE-363Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
SPRX002Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Anitocabtagene autleucelSolid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
Axicabtagene CiloleucelSolid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
Brexucabtagene AutoleucelSolid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
Brexucabtagene AutoleucelMantle Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
KITE-197Solid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
KITE-363Solid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
KITE-753Solid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Study Of KITE-753 in R/R B-Cell ALLPHASE1 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT07674823 · fetched Nov 12, 2026
CD45BE-HSPC + CART-45 CellsPHASE1 · RECRUITING · started Aug 5, 2026ClinicalTrials.gov NCT07451054 · fetched Nov 12, 2026
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyPHASE3 · ACTIVE_NOT_RECRUITING · started May 22, 2026ClinicalTrials.gov NCT07479797 · fetched Nov 12, 2026
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentPHASE1 · RECRUITING · started Apr 10, 2026ClinicalTrials.gov NCT07304154 · fetched Nov 12, 2026
A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesPHASE1 · ENROLLING_BY_INVITATION · started Jul 2, 2025ClinicalTrials.gov NCT07038447 · fetched Nov 12, 2026
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesPHASE1 · RECRUITING · started Apr 30, 2025ClinicalTrials.gov NCT06626919 · fetched Nov 12, 2026
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 23, 2024ClinicalTrials.gov NCT06413498 · fetched Nov 12, 2026
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaPHASE2 · RECRUITING · started May 7, 2024ClinicalTrials.gov NCT06213311 · fetched Nov 12, 2026
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)PHASE2 · RECRUITING · started Dec 26, 2023ClinicalTrials.gov NCT06144606 · fetched Nov 12, 2026
TmCD19-IL18 in CD19+ CancersPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 13, 2023ClinicalTrials.gov NCT05989204 · fetched Nov 12, 2026
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell LymphomaPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 9, 2023ClinicalTrials.gov NCT06079164 · fetched Nov 12, 2026
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLPHASE2 · RECRUITING · started Nov 8, 2023ClinicalTrials.gov NCT06104592 · fetched Nov 12, 2026
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 2, 2023ClinicalTrials.gov NCT05993949 · fetched Nov 12, 2026
Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHLPHASE1 · ACTIVE_NOT_RECRUITING · started May 23, 2023ClinicalTrials.gov NCT05794958 · fetched Nov 12, 2026
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic RetinoblastomaPHASE1 · ENROLLING_BY_INVITATION · started May 23, 2023ClinicalTrials.gov NCT05650749 · fetched Nov 12, 2026
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 10, 2023ClinicalTrials.gov NCT05605899 · fetched Nov 12, 2026
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.PHASE1 · ACTIVE_NOT_RECRUITING · started Nov 28, 2022ClinicalTrials.gov NCT05457010 · fetched Nov 12, 2026
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Nov 18, 2022ClinicalTrials.gov NCT05495464 · fetched Nov 12, 2026
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 22, 2022ClinicalTrials.gov NCT05371093 · fetched Nov 12, 2026
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 15, 2022ClinicalTrials.gov NCT05396885 · fetched Nov 12, 2026
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesENROLLING_BY_INVITATION · started Dec 15, 2021ClinicalTrials.gov NCT05041309 · fetched Nov 12, 2026
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 27, 2021ClinicalTrials.gov NCT04989803 · fetched Nov 12, 2026
Axi-cel in CNS LymphomaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 4, 2020ClinicalTrials.gov NCT04608487 · fetched Nov 12, 2026
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 23, 2019ClinicalTrials.gov NCT04155749 · fetched Nov 12, 2026
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAVAILABLEClinicalTrials.gov NCT05776134 · fetched Nov 12, 2026